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Key points
 Fetal growth restriction (FGR) is a major risk factor for stillbirth and has significant impact
upon lifelong health.
 A small, poorly functioning placenta, as evidenced by reduced transport of nutrients to the
baby, underpins FGR. It remains unclear how a small but normal placenta differs from the
small FGR placenta in terms of ability to transfer nutrients to the fetus.
 Placental transport of glutamine and glutamate, key amino acids for fetal growth, was assessed
in normal mice and those with FGR.
 Glutamine and glutamate transport was greater in the lightest versus heaviest placenta in a
litter of normally grown mice. Placentas of mice with FGR had increased transport capacity in
mid-pregnancy, but this adaptation was insufficient in late pregnancy.
 Placental adaptations, in terms of increased nutrient transport (per gram) to compensate for
small size, appear to achieve appropriate fetal growth in normal pregnancy. Failure of this
adaptation might contribute to FGR.
Abstract Fetal growth restriction (FGR), a major risk factor for stillbirth, and neonatal and
adulthood morbidity, is associated with reduced placental size and decreased placental nutrient
transport. In mice, a small, normal placenta increases its nutrient transport, thus compensating
for its reduced size and maintaining normal fetal growth. Whether this adaptation occurs for
glutamine and glutamate, two key amino acids for placental metabolism and fetal growth,
is unknown. Additionally, an assessment of placental transport of glutamine and glutamate
between FGR and normal pregnancy is currently lacking. We thus tested the hypothesis that the
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transport of glutamine and glutamate would be increased (per gram of tissue) in a small normal
placenta [C57BL6/J (wild-type,WT)mice], but that this adaptation fails in the small dysfunctional
placenta in FGR [insulin-like growth factor 2 knockout (P0) mouse model of FGR]. InWTmice,
comparing the lightest versus heaviest placenta in a litter, unidirectional maternofetal clearance
(Kmf) of 14C-glutamine and 14C-glutamate (glutamineKmf and glutamateKmf) was significantly higher
at embryonic day (E) 18.5, in line with increased expression of LAT1, a glutamine transporter
protein. In P0 mice, glutamineKmf and glutamateKmf were higher (P0 versus wild-type littermates,
WTL) at E15.5. At E18.5, glutamineKmf remained elevated whereas glutamateKmf was similar between
groups. In summary, we provide evidence that glutamineKmf and glutamateKmf adapt according to
placental size in WT mice. The placenta of the growth-restricted P0 fetus also elevates transport
capacity to compensate for size at E15.5, but this adaptation is insufficient at E18.5; this may
contribute to decreased fetal growth.
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Introduction
Placental dysfunction is a major cause of pregnancy
complications such as fetal growth restriction (FGR)
(Mifsud & Sebire, 2014), which is characterised by
poor growth in utero and has immediate and life-long
consequences (Veen et al. 1991; Barker, 2004; Thornton
et al. 2004; Gardosi et al. 2013). One facet of this
placental dysfunction is abnormal nutrient transport by
the syncytiotrophoblast, the transporting epithelium of
the placenta. This has been evidenced by studies in women
demonstrating that the activity of key amino acid trans-
port systems A and L is reduced in FGR (Glazier et al.
1997; Jansson et al. 1998). In addition, animal studies
have shown that reductions in placental system A activity
precede FGR (Jansson et al. 2006; Pantham et al. 2016) and
that blockade of system A by substrate inhibition results
in reduced fetal growth (Cramer et al. 2002). Collectively,
these studies illustrate the importance of placental amino
acid transport for appropriate growth of the fetus and
suggest that reductions in amino acid transportmay result
in FGR.
The amino acids glutamine and glutamate are vital
for metabolic processes and fetal growth. Glutamine is
a conditionally essential amino acid during pregnancy
and studies in sheep have demonstrated that it is trans-
ported to the fetus at one of the highest rates of all amino
acids (Battaglia, 2002; Parimi & Kalhan, 2007), in keeping
with its importance for fetal growth. Many essential cell
processes such as nucleotide synthesis, pH homeostasis
and gluconeogenesis require glutamine (Pochini et al.
2014). Glutamate is a precursor of glutamine and other
molecules such as GABA, glutathione and 2-oxoglutarate.
Glutamate is also a neurotransmitter (Olsen& Sonnewald,
2015) and fetal plasma levels must be carefully controlled
during fetal brain development because high levels of
glutamate are neurotoxic (Tian et al. 2012).
In humans, fetal provision of glutamine and glutamate
is achieved by amino acid recycling between the placenta
and fetal liver. Both amino acids are transported from
maternal blood into the placenta. However, evidence in
humans, sheep and pigs suggests that glutamate is not
transported directly from maternal to fetal blood (Pitkin
et al. 1979; Vaughn et al. 1995; Battaglia, 2002; Self et al.
2004;Day et al. 2013) but instead is converted to glutamine
in the syncytiotrophoblast. Glutamine then effluxes to the
fetus and is converted back to glutamate by the fetal liver.
Any glutamate not utilised by the fetus is taken up by
the placenta to complete the cycle (Moores et al. 1994;
Vaughn et al. 1995). The conversion of glutamine to/from
glutamate within the placenta and fetal liver is important
both for placental metabolism and for provision of amino
acids to the fetus.
Placental transport of glutamine is mediated by
several amino acid transport systems (system A, system
N, system L, system y+L and system ASC) of over-
lapping specificity (Pochini et al. 2014). Systems A,
N and L are known to contribute to placental
uptake of glutamine from maternal blood, whereas the
contribution of system y+L to glutamine transfer across
the maternal-facing microvillous membrane (MVM) of
the human syncytiotrophoblast is negligible (Hill et al.
2014). Similarly, ASCT2, a transporter for system ASC,
is predominantly localised to the basal membrane (BM;
fetal-facing) of the human syncytiotrophoblast (Johnson
& Smith, 1988; Hoeltzli & Smith, 1989). Placental uptake
of glutamate from maternal and fetal blood is mediated
by system XAG-. Recent studies in human placenta have
also demonstrated a role for glutamate as a counter-ion
to mediate placental uptake of xenobiotics and hormones
from fetal circulation (Lofthouse et al. 2015, 2018).
In normal human pregnancy, the concentration ofmost
amino acids, including glutamine, is higher in umbilical
venous blood (flowing from placenta to fetus) than in
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maternal plasma (Holm et al. 2017). There are conflicting
reports regarding the concentration of glutamine in
umbilical venous plasma in FGR compared with normal
pregnancy. Ivorra et al. (2012) demonstrated a reduction
in glutamine concentration in babies of low birth weight
at term (below the 10th centile, corresponding to small
for gestational age (SGA) infants compared to babies of
normal birth weight. However, a recent study reported
higher glutamine concentrations in venous cord blood
of very low birth weight pre-term babies compared with
term infants of normal birth weight (Alexandre-Gouabau
et al. 2013); this finding was replicated by Sanz-Corte´s
et al. (2013) in umbilical venous samples from both
early- and late-onset FGR, again defined by a birth weight
< 10th centile. Both of these studies that demonstrated
increased levels of glutamine in FGR were complicated
by the inclusion of women diagnosed with pre-eclampsia.
Umbilical venous and arterial plasma glutamate (glutamic
acid) concentration is reported to be reduced in human
FGR (Alexandre-Gouabau et al. 2013). In addition,
Macnaught et al. (2015) used nuclear magnetic resonance
imaging to show that the combined spectral contribution
of glutamine/glutamate was reduced in placentas of
human SGA infants versus normal birth weight and the
authors proposed that thismay be a biomarker of placental
dysfunction in utero. A comprehensive assessment of
placental transport of glutamine and glutamate in vivo
in both normal pregnancy and FGR is currently lacking.
The pregnant mouse is a widely used model of human
pregnancy. Like the human placenta, the mouse placenta
is haemochorial (trophoblast tissue bathed in maternal
blood) but in contrast to the human, the fetal portion of
the mouse placenta is formed by two major but distinct
zones: the junctional zone, primarily associated with end-
ocrine function, and the labyrinthine zone, which is the
major site of nutrient exchange (Enders & Blankenship,
1999; Malassine et al. 2003). Thus, the maternofetal
nutrient exchange layer in themouse, as its name suggests,
has a labyrinthine-like structure in contrast to the villous
arrangement in the human placenta. The mouse placenta
is classed as haemotrichorial, versus haemomonochorial
in humans, because there are three trophoblast layers
between maternal and fetal circulations: a discontinuous
(trophoblast giant cell) layer I, syncytial layer II and
fetal-facing layer III. The apical membrane (layer II) is
thought to be akin to the human syncytiotrophoblast
MVM: both stain positively with alkaline phosphatase,
and transporter proteins such as theGLUT1 glucose trans-
porter have been localised to this layer (Enders, 1965;
Takata & Hirano, 1997; Georgiades et al. 2002; Jansson
et al. 2002). Layer III (basal membrane) is posited to be
similar to the human syncytiotrophoblast BM, although
this has not yet been confirmed due to a lack of a current
method to isolate layer III in the mouse (for review
see Dilworth & Sibley, 2013). Studies in pregnant mice,
which enable assessment of nutrient delivery to the fetus
using radioisotopes, have demonstrated that placental
nutrient transport adapts according to placental size, thus
maintaining appropriate fetal growth (Godfrey et al. 1998;
Coan et al. 2008; Dilworth et al. 2010). Maternofetal
transport of both calcium (Hayward et al. 2017) and
the non-metabolisable system A amino acid analogue
methylaminoisobutyric acid (MeAIB) (Coan et al. 2008) is
increased, per gramplacenta, in the lightest versus heaviest
placentas in a litter of wild-type C57Bl/6J (WT)mice. This
adaptation helps to ensure that the fetus is born within a
normal birth weight range. As a substrate of systemA, one
would hypothesise that glutamine transport also adapts
in relation to placental size in WT mice, but, prior to the
current study, this has not been investigated. Furthermore,
no studies, in mice or human, have explored whether the
glutamate transporter system XAG- adapts according to
placental size.
Improvingour knowledgeof thephysiological processes
that regulate nutrient provision to the fetus in normal
pregnancy can inform our understanding of why amino
acid transport is reduced in FGR. Recent research in mice
suggests that the mechanisms underpinning placental
adaptations, at least in terms of placental calcium trans-
fer, are distinct in normally grown and growth restricted
fetuses (Hayward et al. 2018). Therefore, an assessment of
maternofetal placental glutamine and glutamate transfer
in a model of FGR provides the opportunity to assess
whether any adaptations present in normal mice are
altered in placentas of growth-restricted fetuses. Here we
chose a geneticmousemodel of FGR, theplacental-specific
insulin-like growth factor 2 knockout (P0) mouse,
to examine maternofetal transfer of glutamine and
glutamate. The P0 mouse is a model of late-onset
FGR, pups weigh 30% less than WT at birth, which
gives rise to mixed litters of P0 (growth restricted) and
wild-type littermates (WTL). P0 fetuses have significantly
lighter placentas prior to the onset of growth restriction
(Constaˆncia et al. 2002). In this model maternofetal trans-
fer of glucose andMeAIB is significantly higher (P0 versus
WTL) in mid-gestation, a time point when normal fetal
growth ismaintained.However, this functional adaptation
is lost by term and FGR ensues (Constaˆncia et al. 2002,
2005).
The aims of this study were to assess maternofetal
glutamine and glutamate transport in normal pregnancy
(WTmice) and in amodel of FGR (P0mice).We tested the
hypothesis that when comparing lightest versus heaviest
placentas in a normal (WT) litter, the lightest placentas
functionally adapt their glutamine and glutamate
transport capacity to maintain appropriate fetal growth.
We also hypothesised that in the P0mouse (comparing P0
and WTL), this adaptation is disrupted or absent, which
contributes to FGR. To investigate potential mechanisms,
the abundance of putative glutamine and glutamate
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transporter proteins (systems N and L, and XAG-,
respectively) was assessed by Western blot.
Materials and methods
Animals
All experimental procedures were performed in
accordance with the UK Animal (Scientific Procedures)
Act of 1986 under Home Office project licences PPL
40/3385 and P9755892D and were approved by the local
ethical review panel of the University of Manchester.
The methods described herein adhere to the ARRIVE
guidelines (Kilkenny et al. 2010).
Mice were communally housed (except for stud males
that were individually housed) in individually ventilated
cages in rooms with a 12 h light–dark cycle at 21–23°C.
Mice were provided with nesting material and had free
access to food (BK001 diet, Special Diet Services, Essex,
UK) and water (Hydropac watering system, Lab products
Inc., Seaford, Delaware, USA).
Wild-type (WT) C57BL/6J (Envigo, Huntington, UK)
female (10–16 weeks old) and male (10–26 weeks old)
mice weremated, and the lightest versus heaviest placentas
in a litter were compared to examine the extremes of
placental weight in normal pregnancy. The first day
of gestation was determined by the discovery of a
copulation plug [embryonic day (E) 0.5; term = E19.5].
Pregnant female mice were killed at E15.5 or E18.5
(chosen as peak growth of the fetus occurs between
these two time points) by cervical dislocation alone, or
terminal anaesthesia followed by exsanguination (cardiac
puncture) and cervical dislocation (only for unidirectional
maternofetal clearance measures; see below) appropriate
under ASPA schedule 1. A laparotomy and hysterotomy
was then performed. All fetuses were rapidly killed by
cervical dislocation. Placentas and fetuses were rapidly
harvested, blotted and wet weights measured to identify
the lightest and heaviest placentas in a litter. Fetal tail
tips were collected from all fetuses and stored at −20°C
for determination of sex. Placentas and fetuses were
immediately snap frozen and stored at −80°C. Fetal
weight histograms were constructed and a non-linear
regression was performed (Gaussian distribution) from
which individualised fetal weight centiles were calculated
as described previously (Dilworth et al. 2011).
Placental-specific insulin-like growth factor 2 (Igf2)
(P0) knockout mice, which had deletion of the U2
exon of the Igf2 gene, were generated as previously
described (Constaˆncia et al. 2000) and were a kind
gift from Dr Miguel Constaˆncia and Professor Wolf
Reik, University of Cambridge. C57BL/6J female mice
(8–16 weeks old) and males heterozygous for the P0
deletion (10–101 weeks old) were mated and produced
mixed litters of growth-restricted (P0) and wild-type
littermate (WTL) fetuses. Embryonic day was determined
as above. At E15.5 or E18.5 pregnant female mice were
killed and a laparotomy and hysterotomy was performed.
Fetal tail tips were collected from all fetuses and stored at
−20°C for genotype determination. Placentas and fetuses
were weighed, snap frozen and stored at −80°C. The aim
of the study, comparing lightest versus heaviest placentas
or those from P0 versus WTL mice within a single litter,
meant that randomisation or blinding of the samples was
not possible.
Determination of sex
The sex of each fetus was determined according to
a previously published genotyping protocol (Kunieda
et al. 1992); genomic DNA was extracted from fetal
tail tips using DirectPCR lysis reagent (mouse tail)
(Bioquote, York, UK) containing proteinase K (Qiagen,
Manchester, UK) and MyTaq Red Mix (Bioline Ltd,
London, UK) with primers specific to gene sequences for
SRY (Y chromosome; 404 bp; SRY2 5′-TCTTAAACTCTG
AAGAAGAGAC-3′, SRY4 5′-GTCTTGCCTGTATGTGA
TGG-3′) and NDS (X chromosome; 244 bp; NDS3
5′-GAGTGCCTCATCTATACTTACAG-3′, NDS4 5′-TC
TAGTTCATTGTTGATTAGTTGC-3′) (Kunieda et al.
1992). PCRconditionswere as follows; 4mindenaturation
at 94°C; 35 cycles of 1min at 94°C, 1min at 55°Cand1min
at 72°C; and 10 min final extension at 72°C. Samples were
run on a 2% agarose gel and bands were visualised using
an InGenius transilluminator (Sygene Bio, Cambridge,
UK).
Genotyping of P0 knockout mice
Genotype (P0 or WTL) was determined for all fetuses
from P0 dams according to a previously published
genotyping protocol (Constaˆncia et al. 2005; Dilworth
et al. 2010). In brief, genomic DNA was extracted from
fetal tail tips using a DNeasy kit (Qiagen). Igf2 P0+/−
mutants were identified with a specific primer pair to
amplify a 740 bp fragment across the 5 kb deletion
(P0 dF 5′-TCCTGTACCTCCTAACTACCAC-3′ and
P0 dR 5′-GAGCCAGAAGCAAACT-3′) and a primer
to amplify a 495 bp fragment from the WT allele
(5′-CAATCTGCTCCTGCCTG-3′). PCR conditions were
as follows: 4 min denaturation at 94°C; 35 cycles of
1 min at 94°C, 1 min at 56°C and 1 min at 72°C; and
10 min final extension at 72°C. Samples were loaded
with bromophenol blue and run on a 1.5% agarose gel.
Bands were visualised using an InGenius transilluminator
(Sygene Bio).
Unidirectional maternofetal clearance of
14C-glutamine and 14C-glutamate
Unidirectional maternofetal clearance of 14C-glutamine
and 14C-glutamate across the intact placentawas evaluated
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at E15.5 and E18.5 as described previously (Flexner &
Pohl, 1941; Bond et al. 2008; Dilworth et al. 2010).
Mice were anaesthetised with a 300 µl intraperitoneal
injection of 1:1:2 combination of fentanyl/fluanisone
(Hypnorm, VetPharma Ltd, Leeds, UK), Midazolam
(Roche, UK) and sterile H2O (Braun medical Inc.,
Pennsylvania, USA). Then, 0.023 mBq 14C-glutamine and
0.046 mBq 14C-glutamate was made up in 100 µl sterile
phosphate-buffered saline (PBS) and administered via tail
vein cannula confirmed by pre- and post-weighing of the
syringe (Kern EW 150-3M precision balance, Kern and
Sohn, Germany). At approximately 2 min after injection
(between 90 s and 4 min for 14C-glutamine; 90 s and
3 min for 14C-glutamate), dams were exsanguinated
by cardiac puncture; the maternal blood sample was
obtained and centrifuged at 5000 rpm (1845 g) for
5 min to obtain plasma. All fetuses and placentas were
collected, assessed for total radiolabel accumulation and
compared to a maternal plasma disappearance curve (see
below).Unidirectionalmaternofetal clearance (glutamateKmf
or glutamateKmf; µL/min/g placenta) was calculated as pre-
viously described (Dilworth et al. 2010). Unidirectional
maternofetal clearance (Kmf) is the volume of maternal
plasma theoretically cleared of isotope per unit time,
expressed relative to individual placental weight (per gram
of placenta). It can also be helpful to express maternofetal
transfer relative to fetal weight (µL/min/g fetus) or
irrespective of fetal or placental weight (total radioisotope
transfer) to investigate the relationship between nutrient
transfer and fetal/placental weight. The total amount of
nutrients that reach the fetus is a key determinant of
fetal growth. All clearance experiments were carried out
between the hours of 08:00 and 12:00 in the same theatre
room. Comparisons were made between: the lightest and
heaviest placentas from each litter at E15.5 (glutamine
N= 9 litters, n= 9 lightest versus n= 9 heaviest; glutamate
N = 6 litters, n = 6 lightest versus n = 6 heaviest) and
at E18.5 (glutamine N = 8 litters, n = 8 lightest versus
n = 8 heaviest; glutamate N = 7 litters, n = 7 lightest
versus n = 7 heaviest); and between litter averages for P0
and WTL at E15.5 (glutamine N = 6 litters; n = 25 P0,
n = 25 WTL; glutamate N = 7 litters; n = 25 P0, n = 28
WTL) and at E18.5 (glutamine N = 6 litters; n = 26 P0,
n = 19 WTL; glutamate N = 7 litters; n = 33 P0, n = 24
WTL). Only those litters with at least two P0 and twoWTL
were included for analyses.
Maternal plasma 14C-glutamine and 14C-glutamate
disappearance curve
The time at which clearance of 14C-glutamine and
14C-glutamate from the maternal circulation was linear
was determined by the construction of a 14C maternal
plasmadisappearance curve at E15.5 andE18.5 (glutamine
N= 27WT,N= 19 P0; glutamateN= 23WT,N= 17 P0)
and fitted to a one-phase exponential decay model
(r2 >0.5), asdescribedpreviously (Bond et al.2006).There
was no difference in the isotope disappearance curves in
WT and P0 mice (data not shown).
Protein expression
The lightest and heaviest placentas in a WT litter (E15.5
N = 7 litters, E18.5 N = 8 litters; paired comparison
between lightest and heaviest placentas in each litter),
and the placentas of P0 and WTL mice (E15.5 N = 8
litters, E18.5 N = 8 litters; one paired P0 and WTL
placenta per litter selected at random) were homo-
genised and processed as described previously (Bond et al.
2006). Briefly, whole homogenates were separated, by
means of centrifugation, to obtain a membrane-enriched
fraction. SDS-PAGE was performed followed by electro-
transfer to Immobilon-FL PVDF membranes (Millipore
UK Ltd, Watford, UK). Primary antibodies included:
rabbit polyclonal LAT1 (0.5 µg/ml; KE026; TransGenic
Inc, Tokyo, Japan); rabbit polyclonal LAT2 (2 µg/ml;
abx121147; Abbexa, Cambridge, UK for WT mice, due to
discontinuation, 2 µg/ml; ab75610; Abcam, Cambridge,
UK was used for P0 studies); SNAT5 (1.4–1.8 µg/ml;
ab72717; Abcam); EAAT1 (1 µg/ml; ab416; Abcam);
and rabbit monoclonal EAAT2 (2.69 µg/ml; ab178401;
Abcam). Rabbit polyclonal β-actin (2 µg/ml; ab8227;
Abcam) or β-tubulin (2 µg/ml; ab6046; Abcam) was
used as a loading control; when used no difference was
observed in β-actin or β-tubulin expression between
experimental groups. Negative controls were constructed
by omission of primary antibody during optimisation.
Each experimental run included a positive (mouse
brain whole homogenate or human MVM isolate) and
negative (distilled H2O) control. Immunoreactive species
were detected with fluorescence-conjugated secondary
antibodies (Li-COR Biosciences, Cambridge, UK) and
membranes were imaged using an Odyssey Sa Infrared
Imaging System (Li-COR). Signal density was measured
using Image Studio Lite (Li-COR). All signals were in
the linear range of detection. Comparisons were made
separately between lightest and heaviest (E15.5 N = 6/7
litters, E18.5 N = 4/8 litters), and P0 and WTL (E15.5
N = 8 litters, E18.5 N = 6/8 litters).
Statistical analysis
Data fromWT litters are presented as the lightest placenta
as a percentage of the heaviest in a litter (dotted line
is heaviest = 100%). Data from P0 litters are presented
as the litter average of P0 fetuses as a percentage of
WTL (dotted line corresponds to WTL = 100%). Data
are shown as median (range) where the experimental
N = number of litters and n = number of placentas or
fetuses. Litter averageswere used for comparisons between
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 1. Placental weight, fetal weight and fetal weight:placental weight (F:P) ratio in the lightest and heaviest placentas in a WT
litter at embryonic day (E)15.5 (N = 17) and E18.5 (N = 23)
E15.5 E18.5
Lightest Heaviest P value Lightest Heaviest P value
Placental weight (g) 0.078 0.102 <0.001 0.070 0.090 <0.001
(0.070–0.091) (0.080–0.135) (0.052–0.080) (0.079–0.117)
Fetal weight (g) 0.387 0.422 <0.001 1.184 1.238 0.014
(0.245–0.563) (0.343–0.602) (0.959–1.355) (1.001–1.384)
F:P ratio 4.8 4.0 <0.001 17.0 13.7 <0.001
(3.5–6.5) (3.0–5.8) (12.8–21.6) (10.5–15.4)
Data are median (range). Data were analysed by Wilcoxon signed-rank test versus 100%.
P0 andWTL, and thus inclusion criteria were a minimum
of two P0 and two WTL per litter. The solid line on
graphs represents the median value. To calculate sample
sizes (80% statistical power at a 5% significance level)
per experiment, a standardised difference was calculated
based upon data from our previously published studies
(Dilworth et al. 2010; Hayward et al. 2017). Data were
analysed by Wilcoxon signed-rank test versus 100% or
Mann–Whitney test. P < 0.05 was considered statistically
significant.
Results
Placental and fetal weights in the lightest versus
heaviest placentas in a WT litter
The lightest placenta in a WT litter weighed on average
23% less than the heaviest at both E15.5 (N = 17) and
E18.5 (N = 23) (Table 1; Fig. 1A) (P < 0.001). Fetuses
from the lightest placentas were significantly lighter at
E15.5 and E18.5, yet the magnitude of this difference
was smaller towards term (13%, P < 0.001 at E15.5; 5%,
P < 0.05 at E18.5) (Table 1; Fig. 1B). Fetuses with the
lightest placentas had lower fetal weight centiles compared
with heaviest placentas in a litter at E15.5 (median 38.4
versus 58.2; P< 0.001) and E18.5 (median 51.2 versus 71.0;
P < 0.01) but were still within the normal range (10–90th
centile) (datanot shown).Atbothgestational ages, the fetal
weight:placental weight (F:P) ratio, a proxy of placental
efficiency, was significantly higher for fetuses with the
lightest placentas (P < 0.001) (Table 1; Fig. 1C). There
was no difference in litter size between E15.5 (median = 7
fetuses, range 4–9) and E18.5 (median = 7 fetuses, range
6–10).
Unidirectional maternofetal glutamine and glutamate
clearance across the lightest and heaviest placentas in
a WT litter
Unidirectional maternofetal clearance (Kmf) of glutamine
per gramof placenta (µL/min/g placenta)was significantly
higher (P < 0.01) in lightest versus heaviest placentas
at E18.5, but was not different at E15.5 (Fig. 2A).
Maternofetal transfer of glutamine, both per gram of fetus
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Figure 1. Placental weight (A), fetal
weight (B) and fetal weight:placental
weight (F:P) ratio (C) in the lightest and
heaviest placentas in a WT litter at
embryonic day (E)15.5 and E18.5
Data are presented as the lightest placenta as a
percentage of the heaviest in a litter. Black
line = median; dotted line, 100% = heaviest
placenta. ∗P < 0.05, ∗∗∗P < 0.001 Wilcoxon
signed-rank test versus 100%.
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(µL/min/g fetus) (Fig. 2C) and total transfer (µL/min)
(Fig. 2E), was significantly higher in the lightest compared
with the heaviest placentas at E18.5 (P< 0.01 andP< 0.05,
respectively).
Unidirectional maternofetal clearance (Kmf) of
glutamate per gram of placenta was significantly higher
in the lightest compared with the heaviest placentas at
E18.5 (P < 0.05) but not at E15.5 (Fig. 2B). Maternofetal
transfer of glutamate per gram of fetus (µL/min/g fetus)
(Fig. 2D) and total maternofetal transfer of glutamate
(µL/min) (Fig. 2F) were significantly lower in the lightest
placenta at E15.5 (P< 0.05), but not significantly different
at E18.5.
The lightest placentas in a litter are more frequently
from female fetuses, and similarly a greater proportion
of the heaviest placentas in a litter belong to male
fetuses. In this study, 69% (9/13) and 72% (13/18) of
the lightest placentas in a litter were from female fetuses
at E15.5 and E18.5, respectively. At E15.5, 69% (9/13)
of the heaviest placentas were from male fetuses, this
figure was 83% (15/18) at E18.5. However, unidirectional
maternofetal clearance (Kmf, µL/min/g placenta) was not
different according to sex at either E15.5 or E18.5 (litter
mean (range) of female fetuses as a percentage of male
fetuses (100%), with a minimum of two of each sex per
litter: glutamineKmf E15.5 107% (86–120%), E18.5 119%
(89–141%); and glutamateKmf E15.5 105%(87–123%),E18.5
111% (91–136%) (P > 0.05 in all instances).
Expression of placental glutamine and glutamate
transporter proteins in the lightest versus heaviest
placentas in a WT litter
Western blotting was used to determine whether
functional changes were due to altered transporter protein
abundance. Paired comparisons were made between the
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Figure 2. Unidirectional maternofetal clearance (Kmf), maternofetal transfer and total transfer of
glutamine (A, C, E) and glutamate (B, D, F) in the lightest and heaviest placentas in a WT litter at
embryonic days (E)15.5 and E18.5
Data are expressed as the lightest placenta in a litter as a percentage of the heaviest placenta in a litter. Black
line = median; dotted line, 100% = heaviest placenta. ∗P < 0.05, ∗∗P < 0.01 Wilcoxon signed-rank test versus
100%.
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lightest and heaviest placentas in a WT litter (see Fig. 3F
for representative blots). There was no difference in the
expression of the glutamine transporters LAT1, LAT2
and SNAT5 (Fig. 3A–C), and the glutamate transporters
EAAT1 and EAAT2 (Fig. 3D, E) at E15.5. Expression of
LAT2, SNAT5, EAAT1 and EAAT2 was also no different
at E18.5. However, there was a statistically significant
increase in LAT1 protein expression at E18.5 in the lightest
versus heaviest placentas (Fig. 3A).
Placental and fetal weights in P0 versusWTL
Placentas from P0 fetuses were significantly lighter
(P < 0.001) at both gestational ages, weighing 76%
of those from WTL at E15.5, and 74% towards term
(E18.5) (Table 2; Fig. 4A). At E15.5 P0 fetuses weighed
significantly less (96%;P<0.05) thanWTL; this difference
was more pronounced towards term (E18.5 = 85%;
P < 0.001) (Table 2; Fig. 4B). P0 fetuses had a
significantly higher F:P ratio compared with WTL at
E15.5 and E18.5 (P < 0.001) (Table 2; Fig. 4C).
Fetal weight histograms constructed using non-linear
regression (Gaussian distribution) revealed that at E15.5
8% of P0 fetuses were below the 5th centile of WTL
weights (0.33 g), a clinically relevant threshold for FGR.
By E18.5 the majority of P0 fetuses (57%) were below the
5th centile of WTL weights (1.04 g) (Fig. 4D). There was
no difference in litter size between gestational ages (E15.5
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Figure 3. Expression of glutamine [LAT1 (A), LAT2 (B), SNAT5 (C)] and glutamate [EAAT1 (D), EAAT2
(E)] transporter proteins in membrane-enriched placental homogenates (expressed as percentage of
lightest (L) versus heaviest (H) placentas in a WT litter) at embryonic day (E)15.5 (N = 6/7) and E18.5
(N = 4/8)
Densitometric analysis is expressed as a ratio of β-tubulin or β-actin signal. F, representative Western blots of
LAT1, LAT2, SNAT5, EAAT1 and EAAT2 at E15.5 and E18.5 with the corresponding housekeeper protein. Black
line = median; dotted line 100% = heaviest placenta. ∗P < 0.05; Wilcoxon signed-rank test versus 100%.
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Table 2. Placental weight, fetal weight and fetal weight:placental weight (F:P) ratio in P0 and wild-type littermates (WTL) at
embryonic day (E)15.5 (N = 13) and E18.5 (N = 13)
E15.5 E18.5
P0 WTL P value P0 WTL P value
Placental weight (g) 0.077 0.104 <0.001 0.066 0.094 <0.001
(0.065–0.086) (0.089–0.112) (0.057–0.078) (0.076–0.104)
Fetal weight (g) 0.363 0.387 0.02 1.031 1.220 <0.001
(0.351–0.426) (0.346–0.432) (0.837–1.091) (1.108–1.381)
F:P ratio 4.9 3.9 <0.001 15.2 13.6 <0.001
(4.5–6.2) (3.3–4.6) (13.4–16.9) (10.8–15.3)
Data are median (range). Data were analysed by Wilcoxon signed-rank test versus 100%.
median= 8 fetuses, range 6–10; E18.5median= 8 fetuses,
range 4–12).
Unidirectional maternofetal glutamine and glutamate
clearance in P0 versusWTL
Unidirectional maternofetal clearance (Kmf; µl/min/per
g placenta) of glutamine was significantly higher for
P0 compared with WTL fetuses at E15.5 and E18.5
(P < 0.05) (Fig. 5A). Maternofetal glutamine trans-
fer per gram of fetus (µL/min/g fetus) (Fig. 5C) was
significantly higher (P < 0.05; P0 versus WTL) at E18.5
only whereas total maternofetal transfer of glutamine
(µL/min) (Fig. 5E) was significantly lower at E18.5
(P < 0.05). Unidirectional maternofetal clearance (Kmf)
of glutamate was significantly higher for P0 compared
with WTL (P < 0.05) at E15.5 but not at E18.5 (Fig. 5B).
There was no difference in either maternofetal transfer of
glutamate per gram of fetus (µL/min/g fetus) (Fig. 5D) or
totalmaternofetal transfer of glutamate (µL/min) (Fig. 5F)
between P0 and WTL at E15.5 or E18.5.
Expression of placental glutamine and glutamate
transporter proteins in P0 versusWTL
One P0 and one WTL placenta per litter was selected
at random for protein expression studies (see Fig. 6F
for representative blots). The expression of glutamine
transporter proteins (LAT1, LAT2, SNAT5) in placental
membrane preparations was no different between P0
BA C
D
E18.5E15.5
0
40
60
80
100
120
Fe
ta
l w
ei
gh
t 
P0
/W
TL
 
(%
)
****
E18.5E15.5
0
40
60
80
100
120
Pl
ac
en
ta
l w
ei
gh
t 
P0
/W
TL
 
(%
)
******
E18.5E15.5
0
80
100
120
140
160
180
F:
P 
ra
tio
 
P0
/W
TL
 
(%
)
******
0 1.51.00.5
0
5
10
15
20
25
Fetal weight (g)
%
 
of
 
po
pu
la
tio
n
P0
WTL
E18.5
0.60.40.20.0
0
5
10
15
Fetal weight (g)
%
 o
f p
op
ul
at
io
n
P0
WTL
E15.5
Figure 4. Placental weight (A), fetal weight (B) and fetal weight:placental weight (F:P) ratio (C) in P0
and wild-type littermates (WTL) at embryonic day (E)15.5 and E18.5
Data are presented as the litter average of P0 as a percentage of the litter average of WTL. Black line = median;
dotted line, 100% = WTL. ∗P < 0.05, ∗∗∗P < 0.001; Wilcoxon signed-rank test versus 100%. D, fetal weight
distribution curves for P0 and WTL fetuses are shown for E15.5 and E18.5. The dotted line represents the 5th
centile of WTL fetal weights, which was 0.33 g at E15.5 and 1.04 g at E18.5.
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and WTL at either gestational age (E15.5 or E18.5)
(Fig. 6A–C). There was also no difference in expression
of glutamate transporter protein EAAT1 at E15.5 or E18.5
(Fig. 6D). EAAT2 expression was significantly lower at
E18.5 (Fig. 6E).
Discussion
Glutamine and glutamate are essential for the cellular
and metabolic requirements of the placenta and fetus
(Parimi &Kalhan, 2007). Perturbations in placental trans-
port of these amino acids may contribute to reduced
fetal growth (FGR). Maternofetal transfer of glutamine
and glutamate was evaluated by comparing the extremes
of placental weight in WT mice, and P0 versus WTL in
the P0 mouse model of FGR. In WT mice, the light-
est placentas had a greater unidirectional maternofetal
clearance of glutamine and glutamate, per gram placenta,
relative to the heaviest placentas within the same litter.
This adaptation was sufficient to ensure appropriate
delivery of glutamine and glutamate to the fetus at
E18.5. For glutamate, this represents a normalisation of
maternofetal transfer following an observed reduction
at E15.5. In the P0 knockout mouse model of FGR,
increased maternofetal clearance of glutamine, per gram
placenta,was apparent at bothE15.5 andE18.5 inP0 versus
WTL but this adaptation was unable to fully compensate
for the reduced placental size at E18.5, as evidenced
by reduced total maternofetal transfer of glutamine at
E18.5.
These findings are consistent with existing evidence
that the small, normal mouse placenta can functionally
adapt tomeet fetal nutrient requirements. This adaptation
results in a fetus that, whilst still significantly lighter than
a fetus from the largest placenta in a litter (by 6%),
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Figure 5. Unidirectional maternofetal clearance (Kmf), maternofetal transfer and total transfer of
glutamine (A, C, E) and glutamate (B, D, F) in P0 and wild-type littermates (WTL) at embryonic days
(E)15.5 and E18.5
Data are expressed as the litter mean of placentas from P0 fetuses as percentage of the litter mean of WTL. Black
line = median dotted line, 100% = litter mean of WTL placentas. ∗P < 0.05 Wilcoxon signed-rank test versus
100%.
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remains within a normal birth weight range at term, i.e.
is not growth-restricted as is the case for P0 fetuses. A
dominant role of LAT1, expression of which was higher
in the lightest versus heaviest placentas towards term, is
to maintain the amino acid pool within the cell. LAT1
is involved in the uptake of large neutral amino acids
and works in concert with Na+-dependent unidirectional
transporters such as systems A and N (Verrey, 2003;
Pochini et al. 2014). In the context of the study results,
LAT1 may play a role in maintaining the amino acid pool
within the syncytiotrophoblast of the lightest placentas,
thus contributing to the amount of amino acids available
for exchange between the placenta and fetus, whilst net
uptake is achieved via other transporter mechanisms. A
role for system A transporter isoforms cannot be ruled
out; a lack of commercially available antibodies that
reliably produce bands at the predicted size for SNAT1,
SNAT2 and SNAT4means that we were unable to quantify
expression of these transporters. Previous assessment of
gene expression in the lightest versus heaviest placentas in
a WT litter found that expression of the gene encoding
SNAT2 (slc38a2) is higher in the lightest versus heaviest
placentas in a WT litter (other isoforms expressed in
the placenta, slc38a1/SNAT1 and slc38a4/SNAT4, were
unchanged) (Coan et al. 2008). SNAT1 and SNAT2 have
broad substrate specificity, including glutamine, whilst
SNAT4 is generally not considered to transport glutamine
(Schio¨th et al. 2013).
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Figure 6. Expression of glutamine [LAT1 (A), LAT2 (B), SNAT5 (C)] and glutamate [EAAT1 (D), EAAT2
(E)] transporter proteins in membrane-enriched placental homogenates [expressed as percentage of P0
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It is known that homeostatic control of amino acid
concentrations is maintained by sophisticated regulatory
pathways such as the mechanistic target of rapamycin
(mTOR). mTOR is part of a nutrient sensing pathway
stimulated by nutrients such as amino acids and growth
factors. Inhibition of mTOR, which mimics the reduced
activity observed in FGR (Roos et al. 2007), leads to
decreased system A, L and β transporter activity but
no difference in transporter expression (Roos et al.
2009), which suggests that mTOR regulates amino acid
transporters at the post-translational stage. Moreover,
the downstream effects of activated mTOR complex 1
(mTORC1) include inhibition of the NEDD4-2 complex
leading to reduced ubiquitination and degradation of
amino acid transporters such as LAT1 and SNAT2 by
the proteasome. In light of the findings in WT mice, i.e.
altered Kmf of glutamine and glutamate in the absence
of differences in overall protein transporter abundance,
aside from raised LAT1 expression, the mTOR signalling
pathway is a candidate mechanism by which glutamine
clearance is modified and we are currently investigating
whether altered mTOR activity is responsible for the
changes in Kmf of glutamine and glutamate.
In the current study we were unable to account
for the higher maternofetal glutamate clearance in
the lightest WT placentas towards term; expression of
transporters important for glutamate transport were
no different at either gestational age studied. In the
CNS, EAAT2 is post-translationally modified by the
addition of a small ubiquitin-like modifier (SUMO)
to an accessible lysine. SUMOylation causes the trans-
porter to be internalized and available for response from
an intracellular pool (Foran et al. 2014). There is also
evidence that system XAG- activity is increased during
periods of amino acid deprivation in a kidney cell line
(Plakidou-Dymock & McGivan, 1993). It is reasonable
to suggest that post-translational modifications and/or
signalling pathways are important inmediating functional
changes in glutamate delivery in the lightest placentas.
Considering the results from the current study, it is
conceivable that there are distinct mechanisms driving
glutamine and glutamate provision to the fetus. The total
amount of glutamine transfer to the fetus (irrespective
of fetal or placental weight) was significantly higher
for the lightest compared with the heaviest placentas at
E18.5, which highlights the importance of this amino
acid for fetal growth. Conversely, glutamate transfer was
normalised towards term following a significant decrease
earlier in gestation.
Consistent with previously published literature in this
area (Hayward et al. 2017), the lightest placentas in a
litter were more often from females, and the heaviest
placentas predominantly frommales. An assessment of the
contribution of sex, by comparing maternofetal clearance
(Kmf) for the litter mean of females relative to the litter
mean of males, did not yield any significant differences
between groups. Therefore, it is reasonable to conclude
that the contribution of placental size is greater than
that of the sex of the fetus in relation to the functional
adaptations reported here, an observation that we have
previously seen for maternofetal transport of calcium
(Hayward et al. 2017).Within the constraints of a relatively
small WT litter (average of seven fetuses per litter) there
is somewhat limited variation between the lightest female
placenta and the heaviest female placenta, and likewise
for males. Practically it was not feasible to compare these
groups in the current study; a study of this kindwould thus
probably require greater numbers to detect differences and
a strength of the current study is the ability tomake paired
observations within a litter.
We hypothesised that any functional adaptations pre-
sent in the P0 mouse at E15.5 would be lost towards
term, in alignment with apparent growth restriction at
this time. The data in terms of maternofetal clearance
of glutamate, per gram placenta, support this concept:
glutamateKmf was significantly higher (P0 versus WTL) at
E15.5 but similar between groups at E18.5. Contrary
to this hypothesis, unidirectional maternofetal clearance
of glutamine (glutamineKmf), per gram placenta, was
significantly higher in P0 versusWTL both at E15.5 and at
E18.5. However, at E18.5, this adaptation was not enough
to normalise total maternofetal transfer of glutamine
in P0, which was reduced versus WTL. These placental
adaptations, in terms of nutrient transport in P0 mice,
were ultimately insufficient to overcome the challenge of
a small, pathological placenta; at E18.5 P0 fetuses were
significantly smaller than WTL.
Previous studies have shown that relative to placental
size, activity of systemA (MeAIB clearance) is comparable
between P0 and WTL at E18.5 (Constaˆncia et al. 2005). It
is therefore plausible that system L or N are the main
drivers of the altered glutamine transfer at this time
point.However, our investigationofpotentialmechanisms
did not support this – we did not find any significant
differences in system L or N protein expression at either
gestational age. This suggests a role of other mechanisms,
such as the post-translational modifications described
above. Recent evidence focused upon maternofetal trans-
port of calcium indicates that the underlying mechanisms
behind these adaptations in WT mice are distinct from
those in P0 mice (Hayward et al. 2018). The data pre-
sented here indicate that no significant differences in
LAT1 expression were observed between the placentas
of P0 and WTL, in contrast to lightest versus heaviest
placentas. Furthermore, expressionof the glutamate trans-
porter proteinEAAT2was significantly lower atE18.5 inP0
compared with WTL, whereas no difference was observed
inWT litters. In the P0mouse close to term there is higher
glutamine but not glutamate clearance, per gramplacenta,
indicating that the increase is selective for certain amino
C© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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acid transporters. However, placental nutrient provision
remains insufficient to maintain normal fetal growth in
the P0 mouse.
It is important to acknowledge that the expression
of glutamine and glutamate transport proteins was
assessed in membrane-enriched placental homogenates.
This method was chosen because there is currently no
established method to isolate the basal membrane of the
mouse placenta, and isolation of the apical membrane
(Kusinski et al. 2010) would require samples to be
pooled for sufficient sample size and thus would lose
the advantage of paired comparisons. It is possible that
changes inprotein expression in the apicalmaternal-facing
plasmamembrane are not detected optimally if expression
by other membranes in the homogenate makes a sub-
stantial contribution to the transport proteins detected.
Taken together, the data presented in this paper indicate
that there are different strategies to compensate for small
placental size in normally grown (WT, C57BL/6J) and
growth-restricted (P0) fetuses. In WT litters, the lightest
placenta employs strategies to maintain appropriate fetal
growth, which is supported by the findings that Kmf of
glutamine and glutamate is significantly higher across the
lightest versusheaviest placentas towards term.Conversely,
P0placentas fail to support a fetus of an appropriateweight
by term (57% of fetuses are beneath the 5th centile by
E18.5) and the Kmf of glutamate is similar between P0
and WTL fetuses at E18.5. Total maternofetal delivery of
glutamine to the P0 fetus is reduced in P0 versus WTL at
E18.5, which may also help to explain the reduction in
fetal weight observed.
Unlike findings in sheep, pig, rhesus monkey and
human (Stegink et al. 1975; Pitkin et al. 1979; Vaughn
et al. 1995; Self et al. 2004; Day et al. 2013), our studies
indicate that glutamate is delivered to the fetus, pre-
sumably across the BM. Whilst we cannot categorically
rule out that this glutamate is metabolised, e.g. into
glutamine, glucose or lactate, the time course and pre-
vious studies (Stegink et al. 1975) suggest that this is
unlikely. Radioactive counts in the fetus reflect the amount
of radiolabelled glutamate taken up by the placenta (via
system XAG- isoforms). A mechanism of glutamate efflux
in the humanplacenta is via exchange by the organic anion
transporter/transporting polypeptides OAT4/OATP2B1.
However, OAT4 is not present in the mouse (Rizwan &
Burckhardt, 2007; Koepsell, 2013).
In all cases whereKmf is used to assess amino acid trans-
fer across the placenta in mice, it is possible that the time
taken for the radiolabelled isotopes to equilibrate with
intracellular metabolic compartments/amino acid pools
that exist within the placenta (Vela´zquez et al. 1976; Day
et al. 2013; Cleal et al. 2018) could underestimate the true
clearance over the time course of the experiment.
In conclusion, this study provides the first evaluation of
maternofetal transfer of glutamine and glutamate in vivo,
with a specific focusupon the contributionofplacental size
and sex of the fetus to these transfer processes.We provide
evidence of adaptation of placental Kmf of glutamine and
glutamate in relation to placental size in WTmice. Whilst
glutamine transfer was also higher for P0 versus WTL at
both experimental time points, FGR remained evident.
The exact mechanisms that mediate these differences have
not been fully elucidated and therefore should be the focus
of future research. Whilst these studies in mice enable
quantification of radiolabelled amino acids in the fetus,
future efforts should also assess placental glutamine and
glutamate uptake in human FGR if we are to better under-
stand the fundamental pathophysiology of this disorder.
Should the data here be translatable towomen, theywould
indicate that placental uptake of glutamine and glutamate,
and fetal delivery of glutamine, are compromised in
FGR.Alongside glutamine and glutamate placental uptake
studies, future studies should also assess umbilical levels
of glutamine and glutamate in well-defined cohorts of
human FGR, as opposed to the SGA cohorts previously
investigated (Ivorra et al. 2012; Alexandre-Gouabau et al.
2013; Sanz-Corte´s et al. 2013). These studies will be
important moving forward, particularly in the context
of the proposition of glutamine/glutamate as a potential
biomarkerofplacental dysfunction inwomen(Macnaught
et al. 2015). Ultimately, studies such as this one which help
to understand fundamental placental transport processes
inhealth anddisease are likely tobe important inproviding
the knowledge to effectively design therapies for placental
dysfunction.
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